Italy's Recordati 2025 prelim revenue rises

Recordati Industria Chimica E Farmaceutica SpA

17/02/2026 17:27

Overview

Italy pharmaceutical group's 2025 preliminary revenue rises 11.8% yr/yr

EBITDA for 2025 rises 14.5%, margin on net revenue of 37.8%

Company highlights strong performance in Rare Diseases and Specialty & Primary Care

Outlook

Recordati sees FY 2026 net revenue between €2,730 mln and €2,800 mln

Company expects FY 2026 EBITDA between €995 mln and €1,030 mln

Recordati anticipates FY 2026 adjusted net income between €655 mln and €685 mln

Result Drivers

RARE DISEASES GROWTH - Rare Diseases revenue increased by 29.7%, driven by strong volume growth in Endocrinology and Hema-Oncology franchises, with significant contributions from Isturisa and Enjaymo

SPECIALTY & PRIMARY CARE - Specialty & Primary Care revenue grew 2.0%, supported by Urology, Cardiovascular, and Gastrointestinal franchises, despite market slowdown

FX HEADWINDS - Company faced a €64.2 mln adverse FX impact, but maintained strong margins through strategic partnerships and product performance

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EBITDA
EUR 991.10 mln
FY Free Cash Flow
EUR 558.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Recordati Industria Chimica e Farmaceutica SpA is €57.50, about 21.4% above its February 16 closing price of €47.38

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nGNE1mH7S5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)